A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 26
- Registration Number
- NCT03303911
- Locations
- ๐ฌ๐ง
Simbec Research Ltd, Cardiff, United Kingdom
A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT03268343
- Locations
- ๐ฌ๐ง
Simbec Research Ltd, Merthyr Tydfil, United Kingdom
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT01874561
- Locations
- ๐บ๐ธ
Teva Investigational Site 10565, Lenexa, Kansas, United States
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 700
- Registration Number
- NCT01630733
- Locations
- ๐ช๐ธ
Hospital Universitario La Paz, Madrid, Spain
๐บ๐ธUniversity Cancer Institute, Soynton Beach, Florida, United States
๐ช๐ธHospital Universitario Doctor Peset, Valencia, Spain
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 630
- Registration Number
- NCT01578655
- Locations
- ๐บ๐ธ
Georgia Cancer Specialists, P.C., Marietta, Georgia, United States
๐จ๐ฆSunnybrook Health Sciences Centre, Toronto, Ontario, Canada
๐จ๐ฟKrajskรก nemocnice Liberec a.s., Liberec, Czech Republic
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT01497470
- Locations
- ๐บ๐ธ
Teva Investigational Site 002, Detroit, Michigan, United States
๐บ๐ธTeva Investigational Site 001, Dallas, Texas, United States
๐บ๐ธTeva Investigational Site 003, San Antonio, Texas, United States
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 183
- Registration Number
- NCT01454089
- Locations
- ๐บ๐ธ
Seattle Cancer Care Alliance, Seattle, Washington, United States
๐บ๐ธMontefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
๐บ๐ธColumbia University Medical Center, New York, New York, United States
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 1022
- Registration Number
- NCT01188187
- Locations
- ๐ณ๐ฑ
Teva Investigational Site 852, Rotterdam, Netherlands
๐บ๐ธTeva Investigational Site 093, Marina del Rey, California, United States
๐บ๐ธTeva Investigational Site 100, Birmingham, Alabama, United States
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT01083615
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 64
- Registration Number
- NCT00487786
- Locations
- ๐จ๐ฆ
BC Cancer Agency, Vancouver, British Columbia, Canada
๐จ๐ฆJuravinski Cancer Center, Hamilton, Ontario, Canada
๐บ๐ธSeattle Cancer Care Alliance, Seattle, Washington, United States